Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Mucus-Thinning drug also fight inflammation in COPD?

NCT ID NCT07329946

Disease control Sponsor: Pierachille Santus, MD, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test whether the drug erdosteine, added to standard COPD treatment, can reduce inflammation and oxidative stress in the body. Thirty adults with moderate-to-severe COPD will take either erdosteine or their usual inhaled therapy for 30 days. Researchers will analyze blood samples to see how the drug affects immune and stress-related pathways, aiming to understand why it may reduce flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Erdosteine (a mucolytic drug with antioxidant and anti-inflammatory properties)
What this could lead to
If successful, this study could explain how erdosteine helps reduce COPD flare-ups and improve quality of life, potentially leading to better management strategies.
What could go wrong
This is a very small, early-stage exploratory study (30 people) that looks at biological markers, not clinical outcomes. Results may not translate to real-world benefits or be generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 45 years 2. A confirmed COPD diagnosis at least 12 months prior to enrollment 3. Stable clinical conditions, defined as no exacerbations or respiratory infections of any severity in the last 3 months before enrollment 4. Moderate to Severe airflow obstruction (FEV1 30-80 %predicted post bronchodilation. 5. No hospitalizations for any cause in the 3 months prior to enrollment 6. Ability to perform repeatable pulmonary function tests 7. Chronic inhaled therapy with LAMA/LABA or LAMA/LABA/ICS with no changes in dosage in the last 3 before enrollment Exclusion Criteria: 1. NYHA class III and IV heart failure 2. Unstable arrythmia 3. Active malignancy (solid or blood) 4. Chronic treatment with systemic corticosteroids or immunosuppressants 5. Immune depression 6. Known hypersensitivity to erdosteine 7. Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • L. Sacco Hospital

    Milan, 20157, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.